145 related articles for article (PubMed ID: 37758559)
1. Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression.
Salciccia S; Frisenda M; Tufano A; Di Pierro G; Bevilacqua G; Rosati D; Gobbi L; Basile G; Moriconi M; Mariotti G; Forte F; Carbone A; Pastore A; Cattarino S; Sciarra A; Gentilucci A
Clin Genitourin Cancer; 2024 Apr; 22(2):74-83. PubMed ID: 37758559
[TBL] [Abstract][Full Text] [Related]
2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
3. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery.
Sciarra A; Cattarino S; Gentilucci A; Alfarone A; Innocenzi M; Gentile V; Salciccia S
Urol Oncol; 2013 Jul; 31(5):607-14. PubMed ID: 21665494
[TBL] [Abstract][Full Text] [Related]
4. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
[TBL] [Abstract][Full Text] [Related]
5. Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII.
Salonen AJ; Taari K; Ala-Opas M; Sankila A; Viitanen J; Lundstedt S; Tammela TL;
Scand J Urol; 2014 Dec; 48(6):513-22. PubMed ID: 24679247
[TBL] [Abstract][Full Text] [Related]
6. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
7. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
[TBL] [Abstract][Full Text] [Related]
8. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
9. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
[TBL] [Abstract][Full Text] [Related]
10. Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.
Kuo KF; Hunter-Merrill R; Gulati R; Hall SP; Gambol TE; Higano CS; Yu EY
Clin Genitourin Cancer; 2015 Feb; 13(1):10-6. PubMed ID: 25242417
[TBL] [Abstract][Full Text] [Related]
11. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
Ji G; Song G; Huang C; He S; Zhou L
Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
[TBL] [Abstract][Full Text] [Related]
12. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
13. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
Yu EY; Gulati R; Telesca D; Jiang P; Tam S; Russell KJ; Nelson PS; Etzioni RD; Higano CS
J Clin Oncol; 2010 Jun; 28(16):2668-73. PubMed ID: 20421544
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Salvage Radical Prostatectomy for M0 Castration-resistant Recurrent Prostate Cancer: A Reasonable Option in the Era of New Antiandrogen Therapies?
Marra G; Calleris G; Alessio P; Oderda M; Palou J; Joniau S; Piechaud T; Smelzo S; Morlacco A; Sharma V; Tilki D; Van der Poel H; Veerman H; Karnes RJ; Gontero P
Eur Urol Focus; 2021 Jul; 7(4):807-811. PubMed ID: 32414618
[TBL] [Abstract][Full Text] [Related]
15. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
Strum SB; Scholz MC; McDermed JE
Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
[TBL] [Abstract][Full Text] [Related]
16. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085
[TBL] [Abstract][Full Text] [Related]
18. Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy.
Nguyen-Nielsen M; Liede A; Maegbaek ML; Borre M; Harving N; Hernandez RK; Sørensen HT; Ehrenstein V
Cancer Epidemiol; 2015 Aug; 39(4):623-32. PubMed ID: 26100365
[TBL] [Abstract][Full Text] [Related]
19. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis.
Brungs D; Chen J; Masson P; Epstein RJ
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):105-11. PubMed ID: 24686773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
